Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.

News provided by

Jun 17, 2025, 08:22 ET

ATLANTA, June 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's dedication to supporting the rare disease community that goes beyond medicine. Living with or supporting a loved one impacted by this rare disease can be challenging. This scholarship program can help ease the costs associated with education and allow recipients to gain new skills to further their career goals.

This year's 15 scholarship recipients are a diverse group of passionate advocates including people living with MG or caregiving for a parent living with MG. Of the awardees, one-third are graduating high school seniors, with the remainder planning to pursue undergraduate or graduate degrees and certification programs.

"We are so honored to have received such outstanding applications from all over the country. UCB is inspired by the stories not only of the 15 recipients, but of all the applicants. UCB is driven to take meaningful action to meet their unmet needs," said Kim Moran, SVP & Head, U.S. Rare Diseases, UCB. "That's why we are also excited to announce that the company will continue to fund the UCB U.S. Myasthenia Gravis Scholarship into 2026."

"Financially, I face significant challenges as I juggle the costs of school, living expenses, and medical treatments. With this assistance, I can continue to pursue my dream of becoming a nurse and use my experiences to inspire and support others," said Katy M., one of the UCB Myasthenia Gravis Scholarship recipients.

The selection committee for the UCB Myasthenia Gravis Scholarship was made up of people impacted by myasthenia gravis and medical professionals specializing in neuromuscular diseases.

"Serving on the UCB Scholarship Committee was a deeply emotional experience," said Leila Darki, MD, from the University of Southern California. "Each personal story of someone living with myasthenia gravis reflected such resilience and courage. It truly touched my heart. This experience reminded me why our work matters and left me truly inspired."

"It was a meaningful experience serving on the UCB Scholarship Committee. I was genuinely moved by how much these applicants have accomplished despite the obstacles they've faced," said Jerrica Farrias, MS, APRN, from the University of South Florida. "Their determination speaks for itself, and I felt honored to help recognize their hard work."

Congratulations to this year's recipients of the 2025 UCB Myasthenia Gravis Scholarship:

Drew C. – Findlay, Ohio
Deanna C. – Beverly, Massachusetts
Zeña D. – Lake Forest, California
Joseph L. – Seabrook, New Hampshire
Brylee M. – Excelsior Springs, Missouri
Katy M. – Batesville, Indiana
Noelle P. – Pinson, Alabama
Lauren R. – Fallbrook, California
Joleen R. – Clearwater, Florida
Darrius S. – Avon, Indiana
Antonina S. – Katy, Texas
Deric S. – Wetumpka, Alabama
Note: Recipients' names are included with their permission. Some recipients opted not to have their names included in this announcement.

The UCB Myasthenia Gravis Scholarship™ is a trademark of the UCB Group of Companies.

For further information, contact UCB:

U.S. Rare Disease Communications
Daphne Teo
[email protected]
T +1-770-880-7655

About UCB

UCB, Brussels, Belgium (www.ucb.com), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 6.15 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About the UCB Myasthenia Gravis Scholarship™

The UCB Myasthenia Gravis Scholarship offers educational scholarships to people living with myasthenia gravis and their immediate family members who are pursuing further education, whether they are continuing their education or aiming to gain new career skills. The scholarship can be used for an associate's, undergraduate, graduate degree, or specialty/trade school certificate. Scholarship requirements and limitations apply. For more information, please visit www.ucbmgscholarship.com.

Forward looking statements

This press release contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

SOURCE UCB